William Blair Analysts Lower Earnings Estimates for Enovis

Enovis Co. (NYSE:ENOV) – Equities research analysts at William Blair decreased their Q4 2024 EPS estimates for Enovis in a research note issued on Wednesday, November 6th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $0.91 per share for the quarter, down from their previous forecast of $0.95. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis’ Q4 2025 earnings at $0.96 EPS.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. The company’s quarterly revenue was up 21.0% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the stock. JMP Securities initiated coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. JPMorgan Chase & Co. cut their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Evercore ISI cut their price target on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Enovis Trading Up 2.0 %

Shares of ENOV opened at $47.36 on Monday. The company’s fifty day moving average is $42.24 and its 200 day moving average is $45.38. Enovis has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The stock has a market capitalization of $2.65 billion, a PE ratio of -21.63 and a beta of 1.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.27.

Institutional Trading of Enovis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ridgewood Investments LLC acquired a new position in shares of Enovis in the 2nd quarter valued at about $44,000. DekaBank Deutsche Girozentrale acquired a new position in Enovis during the 3rd quarter worth $55,000. Innealta Capital LLC bought a new stake in shares of Enovis in the 2nd quarter worth $65,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after buying an additional 371 shares in the last quarter. Finally, HBK Sorce Advisory LLC acquired a new stake in shares of Enovis during the first quarter worth $226,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.